These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 18699977)

  • 1. Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapy.
    Nandurkar S
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1165-7. PubMed ID: 18699977
    [No Abstract]   [Full Text] [Related]  

  • 2. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy.
    Miyamoto M; Haruma K; Takeuchi K; Kuwabara M
    J Gastroenterol Hepatol; 2008 May; 23(5):746-51. PubMed ID: 18028348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of prokinetic therapy to a PPI in reflux diseases.
    Hsu YC; Lin HJ
    Aliment Pharmacol Ther; 2011 Apr; 33(8):983-4; author reply 984-5. PubMed ID: 21434953
    [No Abstract]   [Full Text] [Related]  

  • 5. New pharmacologic approaches in gastroesophageal reflux disease.
    Armstrong D; Sifrim D
    Gastroenterol Clin North Am; 2010 Sep; 39(3):393-418. PubMed ID: 20951909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prokinetics of gastrointestinal system; its newer aspects with regard to motillity stimulants].
    Hongo M; Satake M
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():382-8. PubMed ID: 11979811
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
    Miyamoto M; Manabe N; Haruma K
    Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New pharmacological agents for the treatment of gastroesophageal reflux disease.
    Vakil N
    Rev Gastroenterol Disord; 2008; 8(2):117-22. PubMed ID: 18641594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study.
    Miwa H; Inoue K; Ashida K; Kogawa T; Nagahara A; Yoshida S; Tano N; Yamazaki Y; Wada T; Asaoka D; Fujita T; Tanaka J; Shimatani T; Manabe N; Oshima T; Haruma K; Azuma T; Yokoyama T;
    Aliment Pharmacol Ther; 2011 Feb; 33(3):323-32. PubMed ID: 21118395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical considerations in GERD (gastroesophageal reflux disease) therapy: focus on cisapride.
    Snape WJ
    Am J Manag Care; 1997 May; 3(5):766-71. PubMed ID: 10184748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prokinetics in the treatment of gastro-oesophageal reflux disease. International symposium. Paris, France, 5 September 1996.
    Heading RC; Baldi F; Holloway RH; Janssens J; Jian R; McCallum RW; Richter JE; Scarpignato C; Sontag SJ; Wienbeck M
    Eur J Gastroenterol Hepatol; 1998 Jan; 10(1):87-93. PubMed ID: 9512959
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological management of GERD: where does it stand now?
    Hershcovici T; Fass R
    Trends Pharmacol Sci; 2011 Apr; 32(4):258-64. PubMed ID: 21429600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom evaluation in gastroesophageal reflux disease.
    Modlin IM; Moss SF
    J Clin Gastroenterol; 2008; 42(5):558-63. PubMed ID: 18364584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
    Friedlander EA; Pallentino J; Miller SK; VanBeuge SS
    J Am Acad Nurse Pract; 2010 Dec; 22(12):674-83. PubMed ID: 21129076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.
    Ren LH; Chen WX; Qian LJ; Li S; Gu M; Shi RH
    World J Gastroenterol; 2014 Mar; 20(9):2412-9. PubMed ID: 24605040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for gastroesophageal reflux disease.
    Boeckxstaens GE
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):481-91. PubMed ID: 19650746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns in paediatric patients with a new diagnosis of gastroesophageal reflux disease.
    Ruigómez A; Hungin AP; Lundborg P; Johansson S; Wallander MA; García Rodríguez LA
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):232-7. PubMed ID: 21258240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-demand requirements of patients with endoscopy-negative gastro-oesophageal reflux disease: H2-blocker vs. proton pump inhibitor.
    Juul-Hansen P; Rydning A
    Aliment Pharmacol Ther; 2009 Jan; 29(2):207-12. PubMed ID: 19006541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of gastroesophageal reflux disease in primary care settings in Spain: SYMPATHY I study.
    Ferrús JA; Zapardiel J; Sobreviela E;
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1269-78. PubMed ID: 19474743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of response to short-term proton pump inhibitor treatment in laryngopharyngeal reflux patients.
    Siupsinskiene N; Adamonis K; Toohill RJ; Sereika R
    J Laryngol Otol; 2008 Nov; 122(11):1206-12. PubMed ID: 18331659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.